TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Source: Newsfilter
Company Restructuring: TC BioPharm plans to reduce its workforce by approximately 20 employees, focusing on a decentralized production model to enhance efficiency and cut operational costs by 55% compared to 2024.
Financial Impact: The strategic shift is expected to save the company about $2.1 million in partial year 2025 and around $4.2 million annually, while also positioning it better for future clinical trials and advancements in cell therapy manufacturing technologies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
